BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Pharmaceuticals to Participate in March Investor Conferences

Supernus (SUPN)SupernusCompany update

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the

Related news

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

SUPNSupernus2026-08-03 10:30 EST

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-05-27 12:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

AXSMAxsome2026-05-27 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

CGTXCognition Therapeutics2026-06-01 11:30 EST

Cognition Therapeutics Participating in Upcoming Investor Conferences

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

SUPNSupernus2026-08-03 10:30 EST

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-07-14 12:30 EST

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

Stock data

Close
45.85 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States